Gastrointestinal/Carcinoid Cancer
Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alfa versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients [SWOG 0518]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH